NASDAQ : PBM

Psyence Biomedical Ltd. — Company profile

Healthcare · Biotechnology · Canada

Last price 3.61 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 13.77M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.

Details

NamePsyence Biomedical Ltd.
SectorHealthcare
IndustryBiotechnology
Employees12
Founded1994
CeoJody Aufrichtig
CountryCanada
ExchangeNASDAQ
Fiscal YearApril - March
Reporting CurrencyUSD
IsinCA74449F4078
Cusip74449F407
Cik1985062
Sic2834

Key executives

NameTitle
Jody AufrichtigCo-Founder, Executive Chairman and Chief Executive Officer
Warwick Ron Corden-LloydChief Financial Officer and Director
Dr. Neil Maresky M.D.Global Head of Clinical Development
Taryn VosGeneral Counsel

Contact

Address121 Richmond Street West, Penthouse Suite 1300, Toronto, ON M5H 2K1, Canada
Phone416-477-1708
Websitehttps://psyencebiomed.com